PAR · ALVIO.PA
Valerio Therapeutics S.A.
€0.51+€0.09 (+22.01%)
Valerio Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.96% below the high.
Loading market information…
PAR · ALNOV.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Novacyt S.A.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Novacyt S.A.’s next earnings report is currently expected on Apr 29, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Novacyt S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€0.51+€0.09 (+22.01%)
Valerio Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.96% below the high.
€0.74+€0.05 (+7.4%)
Theraclion S.A.’s quoted price sits in the upper half of its reported 52-week range, 20.43% below the high.
€0.31€0.00 (0.0%)
Nicox S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.52% below the high.
€0.94-€0.01 (-0.64%)
Diagnostic Medical Systems S.A.’s quoted price sits in the lower half of its reported 52-week range, 37.18% below the high.
€1.43+€0.03 (+2.14%)
Ikonisys S.A.’s quoted price sits in the lower half of its reported 52-week range, 22.28% below the high.
€0.15+€0.00 (+0.54%)
Implanet S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.62% below the high.
€0.10-€0.00 (-0.31%)
Mauna Kea Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 58.36% below the high.
€0.07-€0.00 (-1.07%)
GenSight Biologics S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.91% below the high.
